ORTEXORTEX News
Tracking BONE? Get live short interest, options flow, and signals on ORTEX.Sign up free →
BO
Trader NoteBONE

BONE Shorts Double, but the Float Is Far Too Thin to Squeeze

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 30 Apr 2026, 03:48

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Boron One Holdings Inc. heads into the final days of April with a sharp price drop, a doubling of estimated short interest, and a lending market so sparsely used it barely registers.

The week's most striking number is the 115% jump in estimated short shares since April 20. The reported short count moved from roughly 11,600 to just under 24,900 shares. That sounds dramatic — but context deflates it immediately. The float runs to around 263 million shares. The short position, even after doubling, amounts to less than 0.01% of the freely traded float. There is no meaningful short pressure here. The absolute numbers are too small to move a micro-cap with this share count.

The lending picture reinforces that read. Availability is extremely loose — the borrow market shows effectively zero constraint on new short positions. The 52-week peak for utilisation was just 36.6%, and recent readings have dropped all the way to zero. Cost-to-borrow data is stale, last recorded in early March at 1.78% — a rate that implies no real scramble for borrows. The short score of 26.4 (ranking in the 90th percentile on the short-score factor) and a days-to-cover rank in the 98th percentile look eye-catching in isolation, but they reflect the mechanics of a near-zero absolute position against a thin trading float, not a genuine crowding signal.

The price tells a more pointed story. The stock closed at CAD $0.035 on April 29, down 12.5% on the day and flat on the week — which itself reflects the recovery from an intra-week low. That 12.5% one-day drop on a penny stock with minimal short interest points to thin liquidity and fragile demand rather than any short-driven move. Peers on the ASX — TMB and WCE — fell 19% and 7% respectively on the same day, suggesting sector-wide pressure rather than anything specific to BONE.

The insider ledger is the most consistent signal in the data. Close relative Gwendalyn Fallis made four separate purchases between mid-2024 and early February 2026, accumulating 725,000 shares across that window at prices between CAD $0.04 and $0.05. The most recent transaction — 240,000 shares at $0.05 in February — was small in dollar terms (roughly USD $8,800) but continued a pattern of incremental accumulation. Executive Director James Wallis and the CEO also appear in the buy column from earlier periods. The trades are low-significance in absolute value, but the direction has been one-way across multiple years.

With the next earnings event pencilled in for May 29, the stock enters the pre-result window already at its lower end of its recent price range. The question worth watching is whether the thin liquidity and soft near-term price momentum attract any incremental selling pressure before that date — or whether the absence of any meaningful short position limits the downside velocity.

Stocks in this article

See the live data behind this article on ORTEX.

Open BONE on ORTEX →

How this article was generated

Generated
30 Apr 2026, 03:48
Data as of
30 Apr 2026, 03:48
Prompt version
v1.0
Data sources
Short interestUtilizationEarningsInstitutional positioningORTEX Alpha signals

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.